NASDAQ:DAWN Day One Biopharmaceuticals Q2 2024 Earnings Report $6.67 -0.02 (-0.30%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.72 +0.04 (+0.67%) As of 06/13/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Day One Biopharmaceuticals EPS ResultsActual EPS-$0.05Consensus EPS -$0.75Beat/MissBeat by +$0.70One Year Ago EPSN/ADay One Biopharmaceuticals Revenue ResultsActual Revenue$8.19 millionExpected Revenue$0.90 millionBeat/MissBeat by +$7.29 millionYoY Revenue GrowthN/ADay One Biopharmaceuticals Announcement DetailsQuarterQ2 2024Date7/30/2024TimeTASConference Call DateTuesday, July 30, 2024Conference Call Time7:00AM ETUpcoming EarningsDay One Biopharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, July 8, 2025Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Day One Biopharmaceuticals Earnings HeadlinesDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | finance.yahoo.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | globenewswire.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.June 14, 2025 | Crypto 101 Media (Ad)H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PTJune 5, 2025 | msn.comJonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA ApprovalJune 5, 2025 | msn.comDay One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301June 4, 2025 | seekingalpha.comSee More Day One Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email. Email Address About Day One BiopharmaceuticalsDay One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.View Day One Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Wells Fargo & Company (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
